RathiVIyerMD
Pediatric Hematology & Oncology • Jackson, MSProfessor, Pediatrics, University of Mississippi School of Medicine
Dr. Iyer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2500 N State St
Jackson, MS 39216Phone+1 601-984-2716
Education & Training
Children's Hospital of MichiganFellowship, Pediatric Hematology/Oncology, 1970 - 1972- Children's Hospital of MichiganResidency, Pediatrics, 1968 - 1970
Osmania Medical College NTR UHSClass of 1966
Certifications & Licensure
MS State Medical License 1973 - 2025- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia Start of enrollment: 2000 Aug 01
- Effectiveness of Arginine as a Treatment for Sickle Cell Anemia Start of enrollment: 2004 Jun 01
Publications & Presentations
PubMed
- 31 citationsIncreased prevalence of potential right-to-left shunting in children with sickle cell anaemia and stroke.Michael M. Dowling, Charles T. Quinn, Claudio Ramaciotti, Julie Kanter, Ifeyinwa Osunkwo
British Journal of Haematology. 2017-01-01 - 17 citationsTherapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overloadBanu Aygun, Nicole A. Mortier, Karen Kesler, Alexandre Lockhart, William H. Schultz
British Journal of Haematology. 2015-04-01 - 31 citationsHydroxyurea and Growth in Young Children With Sickle Cell DiseaseSohail Rana, Patricia E. Houston, Winfred C. Wang, Rathi V. Iyer, Jonathan C. Goldsmith
Pediatrics. 2014-09-01
Grant Support
- Blood Safety Surveillance Among Persons With Sickle Cell Disease In MississippiCenters For Disease Control And Prevention2012
- Pediatric Hydroxyurea Phase III Clinical TrialDivision Of Blood Diseases And Resources2000
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
